Since the year 2000, Peg-Bio's R&D team has been focusing on the research and development of innovative biological products, mainly recombinant protein drugs and peptide drugs. Thanks to its 20+ years of experience, Peg-Bio now owns four core technology platforms with global intellectual property, and a strong pipeline based on these technology platforms. As of Sep. 2022, 8 drug candidates are in clinical trial (Phase I-III), 1 at pre-IND and 6 more FIC (First-in-class) biologics in preclinical study (3 under GLP evaluation, estimated to apply IND in 2023; 3 in CMC study). In the meantime, Peg-Bio has licensed out nearly 10 biologics to top-ranking pharmaceutical companies in China. Along with its innovative drug development, Peg-Bio has gained deep understanding and rich experience in recombinant proteases which are used for insulin/peptide production. And its recombinant Peptide Intermediates stand for top quality as well. To accommodate the needs from international clients for high-quality Proteases & Peptide Intermediates, Peg-Bio has built 3 workshops (fermentation scales from 100L, 1,5000L to 3,000L), with the latter 2 workshops being operated in according with GMP. Peg-Bio has two wholly-owned subsidiaries, IMED BioSciences and Zyme Biotech. IMED BioSciences specializes in the development, manufacture and global sales of recombinant Proteases and Peptide Intermediates. Zyme Biotech, located in Canada, focuses on the R&D of advanced innovative biologic drugs.